Gerresheimer's H1 2025 Financial Performance: Bormioli Pharma Boost

Gerresheimer AG reported a solid financial performance in the first half of 2025, with Bormioli Pharma, acquired in 2024, contributing positively. Revenues increased by 15.7% to EUR 1,120.7 million, while adjusted EBITDA rose by 11.8% to EUR 210.4 million. However, when compared to 2024 pro forma figures, organic revenues declined by 2.1% and adjusted EBITDA by 6.4%, reflecting subdued demand in the cosmetics and oral liquids market.

The Plastics & Devices division saw revenues increase by 19.8%, driven by strong demand for drug delivery systems. Despite overall market weakness, the adjusted EBITDA margin remained resilient. Meanwhile, the Primary Packaging Glass division experienced an 11.3% revenue rise, although organic revenues were down 7.6% due to sluggish demand.

Looking ahead, Gerresheimer anticipates stronger growth in the second half of 2025 with new production line ramp-ups and expanded high-value solutions contributing to the positive outlook. The company expects organic revenue growth of 0-2% and a 20% EBITDA margin for the full year.